Cilengitide "promotes cancer growth"

29 March 2009

Cancer Research UK-funded scientists have found evidence to suggest that low doses of Merck KGaA's cilengitide in laboratory studies can have the  opposite effect to that expected and promote cancer growth, according to  research published in Nature Medicine. The German drugmaker's  investigational integrin inhibitor recently entered mid-stage testing  (Marketletter March 23).

Lead study author, Andy Reynolds, said: "our study revealed a previously  unknown mechanism through which drugs such as cilengitide behave. It  showed that, while higher concentrations of cilengitide can block  angiogenesis, lower concentrations can actually stimulate the supply of  blood to the tumor and can promote its growth. These results may explain  why initial results from early-stage clinical trials have not been as  promising as hoped."

Commenting on the findings, Merck KGaA spokesperson Phyllis Carter said:  "the data presented in this paper are of interest to the overall debate  as to the mode of action of integrin inhibitors. However, it does not  reflect previous findings in other preclinical models in vivo or in  vitro, either as single agent or in combination. Even more important the  observations of Reynolds et al in preclinical models have not been  reflected in clinical settings."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight